A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI Community,

As we approach the midpoint of the year, and peak springtime here in the US, we are excited about FAPI achievements and what remains in bloom.

I appreciated the opportunity to participate in PEGS Boston in May and see the discourse around radiopharmaceuticals continue to evolve.  SOFIE was also a proud sponsor of the recent ICPO Forum for Theranostics in Precision Oncology. (Photographed above are our SOFIE apples at the event.)

Looking ahead, on Wednesday, June 18, 12:30 pm PDT, I’m presenting a webinar, “Current State of FAP Targeting Radioligands in Oncology”. Register here. 

Immediately following is the annual SNMMI meeting in New Orleans, LA, on June 21-24.  SOFIE is hosting our 4th Satellite Symposium, “A Target of Opportunity: Shaping the Future of FAPI” on Sunday, June 22, 6:30 pm (details below).  We hope you’ll visit us at the SOFIE Booth (1301) with any questions you may have.  Partners, please contact us if you’d like to schedule a meeting at SNMMI.  We can’t wait to see you!

Please kindly share your feedback on how this newsletter can better serve you and your interest in FAPI.

Sherly Mosessian, Ph.D.

– Sherly Mosessian, Ph.D., Chief Scientific Officer

FAPI-74 CLINICAL DEVELOPMENT UPDATE

FAPI Pipeline Winter 2025

UPCOMING EVENT

A target of opportunity - shaping the future of FAPI

PUBLICATION HIGHLIGHTS

Each newsletter will feature recent FAPI publications.

Liver fibrosis is a chronic fibrosing hepatic disorder following recurrent injury, characterized by the excessive accumulation of extracellular matrix.

Efficacy of [68Ga]Ga-FAPI-PET as a non-invasive evaluation method of liver fibrosis

Ann Nucl Med. 2025 Mar 6

Comparison of [99mTc]Tc-FAPI SPECT/CT and [18F]FDG PET/CT as predictive biomarkers for immunotherapy response in gastrointestinal cancer

Comparison of [99mTc]Tc-FAPI SPECT/CT and [18F]FDG PET/CT  as predictive biomarkers for immunotherapy response in gastrointestinal cancer

Sci Rep. 2025 May 14

FAPI OUTREACH PROGRAM

Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program

SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.

*GE Healthcare licensed products and regions are accepting new applications.

Copyright 2025 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.